In recent years, the incidence of hyperlipidemia acute pancreatitis (HLAP) has been increasing year by year, but its pathogenesis has not been completely clear. There are many clinical treatment methods for HLAP, such as lipid-lowering drugs, low molecular weight heparin, insulin, and plasma exchange. Actively reducing serum triglyceride is the core of treatment. Plasma exchange can quickly and effectively reduce the level of triglyceride, and its application in the treatment of HLAP is gradually increasing. This article reviews the recent advances in the pathogenesis, clinical characteristics, diagnosis, and treatment of HLAP, focusing on the mechanism, indications, timing, and disadvantages of plasma exchange therapy for HLAP.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which pancreatic β cells are destroyed, resulting in an absolute lack of insulin. Intestinal microbiota and its metabolites can promote the progression of T1DM by destroying pancreatic β cells, increasing insulin resistance, increasing intestinal permeability, interfering with immune response. Therefore, fecal microbiota transplantation is expected to become a new method for preventing and treating T1DM in the future. This article mainly explores possible pathways for the application of fecal microbiota transplantation in T1DM, including protection of pancreatic β cells, improving insulin resistance, reducing intestinal permeability, and regulating immune responses.